본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색
결과 내 검색 동의어 포함
결과 내 검색 동의어 포함

-

초록보기

Purpose In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC. Materials and Methods Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed. Results Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p 〈 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002). Conclusion Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
Applicability of spatial technology in cancer research Sangjeong Ahn, Hye Seung Lee p. 343-356

Cancer statistics in Korea : incidence, mortality, survival, and prevalence in 2021 Eun Hye Park, Kyu-Won Jung, Nam Ju Park, Mee Joo Kang, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo, Community of Population-Based Regional Cancer Registries p. 357-371

Prediction of cancer incidence and mortality in Korea, 2024 Kyu-Won Jung, Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo p. 372-379

Health inequities in cancer incidence according to economic status and regions are still existed even under universal health coverage system in Korea : a nationwide population based study using National Health Insurance Database Youngs Chang, Soo-Hee Hwang, Sang-A Cho, Hyejin Lee, Eunbyul Cho, Jin Yong Lee p. 380-403

Impact of patient sex on adverse events and unscheduled utilization of medical services in cancer patients undergoing adjuvant chemotherapy : a multicenter retrospective cohort study Songji Choi, Seyoung Seo, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jwa Hoon Kim ... [et al.] p. 404-413

Radiation oncologists’ perspectives on oligometastatic disease : a Korean survey study Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Ah Ram Chang, Eui Kyu Chie, Yong Chan Ahn p. 414-421

(The) real-world outcome of first line atezolizumab in extensive-stage small cell lung cancer : a multicenter prospective cohort study Myeong Geun Choi, Yeon Joo Kim, Jae Cheol Lee, Wonjun Ji, In-Jae Oh, Sung Yong Lee, Seong Hoon Yoon, Shin Yup Lee, Jeong Eun Lee, Eun Young Kim, Chang-Min Choi p. 422-429

Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer : implications for thoracic radiotherapy Dowook Kim, Hak Jae Kim, Hong-Gyun Wu, Joo Ho Lee, Suzy Kim, Tae Min Kim, Jin-Soo Kim, Byoung Hyuck Kim p. 430-441

Genomic landscape of pulmonary sarcomatoid carcinoma Hyun Jung Kwon, Sejoon Lee, Yeon Bi Han, Jeonghyo Lee, Soohyeon Kwon, Hyojin Kim, Jin-Haeng Chung p. 442-454

Tissue and plasma-based highly sensitive blocker displacement amplicon nanopore sequencing for EGFR mutations in lung cancer Patinya Akkhasutthikun, Pornchai Kaewsapsak, Pattaraporn Nimsamer, Pavit Klomkliew, Suthida Visedthorn, Pragwalai Chanchaem, Chinachote Teerapakpinyo, Sunchai Payungporn, Sutima Luangdilok p. 455-463

Development of the Korean association for lung cancer clinical practice guidelines : recommendations on radial probe endobronchial ultrasound for diagnosing lung cancer : an updated meta-analysis Soo Han Kim, Hyun Sung Chung, Jinmi Kim, Mi-Hyun Kim, Min Ki Lee, Insu Kim, Jung Seop Eom p. 464-483

Revolutionizing non–small cell lung cancer diagnosis : ultra-high-sensitive ctDNA analysis for detecting hotspot mutations with long-term stored plasma Ji-Young Lee, Seyeon Jeon, Ha Ra Jun, Chang Ohk Sung, Se Jin Jang, Chang-Min Choi, Sung-Min Chun p. 484-501

Clinical effect of endosonography on overall survival in patients with radiological N1 non-small cell lung cancer Bo-Guen Kim, Byeong-Ho Jeong, Goeun Park, Hong Kwan Kim, Young Mog Shim, Sun Hye Shin, Kyungjong Lee, Sang-Won Um, Hojoong Kim, Jong Ho Cho p. 502-512

Pyrotinib combined with vinorelbine in patients with previously treated HER2-positive metastatic breast cancer : a multicenter, single-arm, prospective study Kuikui Jiang, Ruoxi Hong, Wen Xia, Qianyi Lu, Liang Li, Jianhao Huang, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Xin An ... [et al.] p. 513-521

Temporal trend in uptake of the national general health checkups and cancer screening program among Korean women with breast cancer Thi Xuan Mai Tran, Soyeoun Kim, Chihwan Cha, Boyoung Park p. 522-530

Implication of pre- and post-radiotherapy ctDNA dynamics in patients with residual triple-negative breast cancer at surgery after neoadjuvant chemotherapy : findings from a prospective observational study Tae Hoon Lee, Haeyoung Kim, Yeon Jeong Kim, Woong-Yang Park, Won Park, Won Kyung Cho, Nalee Kim p. 531-537

Genomic characteristics and its therapeutic implications in breast cancer patients with detectable molecular residual disease Shu Zhang, Yan Jiang, Lu Zhou, Jing Xu, Gang Zhang, Lu Shen, Yan Xu p. 538-548

Assessment of eligibility and utilization of accelerated partial breast irradiation (APBI) in Korean breast cancer patients (KROG 22-15) Seok-Joo Chun, Ji Hwan Jo, Yong Bae Kim, Sangjoon Park, Sung-Ja Ahn, Su Ssan Kim, Kyubo Kim, Kyung Hwan Shin p. 549-556

PD-L1 (SP142) expression in primary and recurrent/metastatic triple-negative breast cancers and its clinicopathological significance Eun Kyung Han, Ji Won Woo, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park p. 557-566

Neoadjuvant nivolumab therapy for esophageal squamous cell carcinoma : a single-arm, phase Ⅱ study Sehhoon Park, Yurimi Lee, Jiyun Lee, Yang Won Min, Hong Kwan Kim, Joon Young Choi, Hyun Ae Jung, Yong Soo Choi, Yoon-La Choi, Young Mog Shim, Jong-Mu Sun p. 567-579

NESC multicenter phase Ⅱ trial in the preoperative treatment of gastric adenocarcinoma with chemotherapy (docetaxel-cisplatin-5FU+lenograstim) followed by chemoradiation based 5FU and oxaliplatin and surgery Laurent Mineur, Frederi Plat, Françoise Desseigne, Gael Deplanque, Mohamed Belkacemi, Laurence Moureau-Zabotto, Carlos D. Beyrne, Khadija Jalali, Stéphane Obled, Denis Smith, Léa Vazquez, Rania Boustany p. 580-589

(A) phase 1b/2a study of GC1118 with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in patients with recurrent or metastatic colorectal cancer Keun-Wook Lee, Sae-Won Han, Tae Won Kim, Joong Bae Ahn, Ji Yeon Baek, Sang Hee Cho, Howard Lee, Jin Won Kim, Ji-Won Kim, Tae-You Kim ... [et al.] p. 590-601

(A) single-arm phase Ⅱ study of nab-paclitaxel plus gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer Ting Liu, Qing Li, Zhen Lin, Chunhua Liu, Wei Pu, Shasha Zeng, Jun Lai, Xuebin Cai, Lisha Zhang, Shuyang Wang, Miao Chen, Wei Cao, Hongfeng Gou, Qing Zhu p. 602-615

Physical activity and bladder cancer risk : findings of the Japan collaborative cohort study Hang An, Keyang Liu, Kokoro Shirai, Ryo Kawasaki, Akiko Tamakoshi, Hiroyasu Iso p. 616-623

Clinical outcomes of small cell carcinoma of the genitourinary tract and the prognostic significance of the tumor immune microenvironment Jaewon Hyung, Hyung-Don Kim, Gi Hwan Kim, Yong Mee Cho, Yeon-Mi Ryu, Sang-Yeob Kim, Inkeun Park, Shinkyo Yoon, Jae Lyun Lee p. 624-633

Oncological outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide with versus without confirmatory bone scan Chang Wook Jeong, Jang Hee Han, Dong Deuk Kwon, Jae Young Joung, Choung-Soo Kim, Hanjong Ahn, Jun Hyuk Hong, Tae-Hwan Kim, Byung Ha Chung, Seong Soo Jeon ... [et al.] p. 634-641

Tandem high-dose chemotherapy increases the risk of secondary malignant neoplasm in pediatric solid tumors Hana Lim, Minji Im, Eun Seop Seo, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Sung Yoon Cho, Jong-Won Kim, Do Hoon Lim, Ki Woong Sung, Ji Won Lee p. 642-651

Long-term outcomes of protocol-based treatment for newly diagnosed medulloblastoma Won Kee Ahn, Seung Min Hahn, Hong In Yoon, Jeongshim Lee, Eun Kyung Park, Kyu Won Shim, Dong Seok Kim, Chang-Ok Suh, Se Hoon Kim, Chuhl Joo Lyu, Jung Woo Han p. 652-664

Case series of soft tissue sarcoma patients with brain metastasis with implications from genomic and transcriptomic analysis Changhee Park, Rokhyun Kim, Jaeyong Choi, Miso Kim, Tae Min Kim, Ilkyu Han, Jong-Il Kim, Han-Soo Kim p. 665-674

(A) phase Ⅱ study to evaluate the efficacy of bortezomib in combination with thalidomide in treatment : naïve waldenstrom macroglobulinemia patients Ja Min Byun, Junghoon Shin, Sang-A Kim, Hyunkyung Park, Jiyun Lee, Dong-Yeop Shin, Junshik Hong, Jeong-Ok Lee, Soo-Mee Bang, Inho Kim, Sung-Soon Yoon, Youngil Koh p. 675-680

Pembrolizumab for patients with relapsed or refractory extranodal NK/T-cell lymphoma in Korea Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee p. 681-687

Assessment of bone marrow involvement in extranodal NK/T-cell lymphoma : positron emission tomography versus bone marrow biopsy, and the significance of minimal involvement by EBV+ cells (KROG 18-09) Tae Hoon Lee, Hyun Ju Kim, Jong Hoon Lee, Jeongshim Lee, Jin Hee Kim, Dongryul Oh, Keun-Yong Eom p. 688-696

참고문헌 (25건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 J Clin Oncol. 2016 Apr 20;34(12):1402-18 미소장
2 Investig Clin Urol. 2020 Jan;61(1):19-27 미소장
3 J Nucl Med. 1988 Aug;29(8):1354-9 미소장
4 Nat Rev Drug Discov. 2021 Sep;20(9):663-664 미소장
5 N Engl J Med. 2014 Jul 31;371(5):424-33 미소장
6 Bone. 2022 May;158:115783 미소장
7 AJR Am J Roentgenol. 1979 Jun;132(6):927-31 미소장
8 N Engl J Med. 2012 Sep 27;367(13):1187-97 미소장
9 Cancer. 2018 Jul 1;124(13):2801-2814 미소장
10 Clin Genitourin Cancer. 2022 Jun;20(3):270-277 미소장
11 J Biomed Inform. 2009 Apr;42(2):377-81 미소장
12 Medicine (Baltimore). 2017 Jul;96(27):e7223 미소장
13 Clin Genitourin Cancer. 2018 Oct;16(5):349-354 미소장
14 CA Cancer J Clin. 2022 Jan;72(1):7-33 미소장
15 Investig Clin Urol. 2016 May;57(3):174-83 미소장
16 Ther Adv Med Oncol. 2021 Feb 24;13:1758835920987654 미소장
17 Clin Cancer Res. 2011 Jul 15;17(14):4854-61 미소장
18 JAMA Oncol. 2020 Feb 1;6(2):217-225 미소장
19 Prostate Cancer Prostatic Dis. 2020 Mar;23(1):81-87 미소장
20 Cancer Causes Control. 2021 Dec;32(12):1365-1374 미소장
21 Eur Urol Focus. 2016 Dec;2(5):488-498 미소장
22 BJU Int. 2014 Dec;114(6b):E25-E31 미소장
23 J Clin Oncol. 2008 Mar 1;26(7):1148-59 미소장
24 Ann Nucl Med. 2020 Jul;34(7):476-485 미소장
25 Prostate Cancer Prostatic Dis. 2019 Mar;22(1):150-158 미소장

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차